192 related articles for article (PubMed ID: 6588479)
21. Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections.
Ohlin B; Cederberg A; Forssell H; Solhaug JH; Tveit E
Eur J Surg; 1999 Sep; 165(9):875-84. PubMed ID: 10533765
[TBL] [Abstract][Full Text] [Related]
22. Randomized study of minocycline + gentamicin compared with metronidazole + gentamicin for prophylaxis or treatment of mixed infections in abdominal surgery.
Legrand JC; Van der Auwera P; Renaux J; Bailly A; Van Eukem P; Chastel C
Int J Clin Pharmacol Res; 1986; 6(5):361-8. PubMed ID: 3781699
[TBL] [Abstract][Full Text] [Related]
23. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
[TBL] [Abstract][Full Text] [Related]
24. Carbapenems: monotherapy in intra-abdominal sepsis.
Wilson SE
Scand J Infect Dis Suppl; 1995; 96():28-33. PubMed ID: 7652500
[TBL] [Abstract][Full Text] [Related]
25. Current experience with clindamycin in the treatment of abdominal and female pelvic infections.
Gorbach SL
Scand J Infect Dis Suppl; 1984; 43():82-8. PubMed ID: 6398909
[TBL] [Abstract][Full Text] [Related]
26. Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections.
Wacha H; Warren B; Bassaris H; Nikolaidis P;
Surg Infect (Larchmt); 2006 Aug; 7(4):341-54. PubMed ID: 16978077
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males.
Clay PG; Graham MR; Lindsey CC; Lamp KC; Freeman C; Glaros A
Am J Geriatr Pharmacother; 2004 Sep; 2(3):181-9. PubMed ID: 15561650
[TBL] [Abstract][Full Text] [Related]
28. Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections.
Madan AK
Clin Ther; 2004 Oct; 26(10):1564-77. PubMed ID: 15598473
[TBL] [Abstract][Full Text] [Related]
29. [Fosfomycin. II. Antimicrobial activity in vivo].
Carlone NA; Cuffini AM; Savoia D
G Batteriol Virol Immunol; 1977; 70(7-12):215-25. PubMed ID: 615746
[No Abstract] [Full Text] [Related]
30. [Fosfomycin in a hematology department].
Dinelli CA; Montrasio PL; Tansini G
Minerva Med; 1978 Dec; 69(59):4111-4. PubMed ID: 740308
[No Abstract] [Full Text] [Related]
31. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae.
Ribes S; Taberner F; Domenech A; Cabellos C; Tubau F; Liñares J; Viladrich PF; Gudiol F
J Antimicrob Chemother; 2006 May; 57(5):931-6. PubMed ID: 16507562
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.
Roussos N; Karageorgopoulos DE; Samonis G; Falagas ME
Int J Antimicrob Agents; 2009 Dec; 34(6):506-15. PubMed ID: 19828298
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis.
Schwebke JR; Desmond RA
Clin Infect Dis; 2007 Jan; 44(2):213-9. PubMed ID: 17173219
[TBL] [Abstract][Full Text] [Related]
34. [Fosfomycin in urogenital infections. Experimental assumptions and clinical results].
Savoia D; Fontana G; Laudi M; Cauda F
Minerva Med; 1978 Dec; 69(59):4087-91. PubMed ID: 740304
[No Abstract] [Full Text] [Related]
35. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults.
Yellin AE; Hassett JM; Fernandez A; Geib J; Adeyi B; Woods GL; Teppler H;
Int J Antimicrob Agents; 2002 Sep; 20(3):165-73. PubMed ID: 12385694
[TBL] [Abstract][Full Text] [Related]
36. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
Goldstein EJ; Snydman DR
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii29-36. PubMed ID: 15150181
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis: ertapenem for complicated intra-abdominal infections.
Falagas ME; Peppas G; Makris GC; Karageorgopoulos DE; Matthaiou DK
Aliment Pharmacol Ther; 2008 May; 27(10):919-31. PubMed ID: 18266994
[TBL] [Abstract][Full Text] [Related]
38. Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis.
Buyne OR; Bleichrodt RP; van Goor H; Verweij PE; Hendriks T
Br J Surg; 2008 Oct; 95(10):1287-93. PubMed ID: 18720460
[TBL] [Abstract][Full Text] [Related]
39. [Clinical experiments in the use of fosfomycin in oral microbial infections].
Quaranta M
Dent Cadmos; 1983 Mar; 51(3):57-64. PubMed ID: 6576933
[No Abstract] [Full Text] [Related]
40. [Can fosfomycin reduce the nephrotoxicity of aminoglycosides?].
Morin JP; Olier B; Viotte G; Fillastre JP
Pathol Biol (Paris); 1984 May; 32(5):338-42. PubMed ID: 6739142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
